Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis
Saved in:
| Published in: | ClinicoEconomics and Outcomes Research |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867301677692878849 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | ClinicoEconomics and Outcomes Research |
| description | |
| discipline_display | Health and Safety |
| discipline_facet | Health and Safety |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:69262 |
| institution | FRELIP |
| journal_source_facet | ClinicoEconomics and Outcomes Research |
| publishDate | 2026 |
| publishDateSort | 2026 |
| record_format | rss_article |
| spellingShingle | Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis Health and Safety General Health and Safety |
| sub_discipline_display | General |
| sub_discipline_facet | General |
| subject_display | Health and Safety General Health and Safety Health and Safety General Health and Safety |
| subject_facet | Health and Safety General Health and Safety |
| title | Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis |
| title_auth | Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis |
| title_full | Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis |
| title_fullStr | Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis |
| title_full_unstemmed | Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis |
| title_short | Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis |
| title_sort | nivolumab-avd versus brentuximab vedotin-avd as first-line treatment for advanced-stage classical hodgkin lymphoma: a cost-effectiveness analysis |
| topic | Health and Safety General Health and Safety |
| url | https://www.dovepress.com/nivolumab-avd-versus-brentuximab-vedotin-avd-as-first-line-treatment-f-peer-reviewed-fulltext-article-CEOR |